Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Fewer radiation sessions before sarcoma surgery shows promise in early trial

NCT ID NCT02634710

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a shorter course of radiation (hypofractionated) given before surgery for soft tissue sarcoma of the arm, leg, or chest wall. The goal was to see if this approach is safe, feasible, and controls the tumor locally. Thirty-five adults with localized sarcoma completed the treatment, and researchers measured recurrence and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hypofractionated radiation therapy
What this could lead to
If successful, this shorter radiation schedule could become a standard option before surgery for soft tissue sarcoma, reducing treatment time while maintaining tumor control.
What could go wrong
This is a small pilot study with only 35 participants and no comparison group. The results may not apply to all sarcoma types or locations, and the higher daily radiation dose could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Feb 2016

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years of age * Core needle biopsy obtained * Pathologic confirmation of primary soft tissue sarcoma of the upper or lower extremity or chest-wall. * Stage I-III Soft Tissue Sarcoma of the extremity without evidence of metastatic disease * Medically operable * No prior radiotherapy to primary site or adjacent site that results in overlapping radiation fields. * MRI obtained of the affected extremity or chest-wall * CT chest acquired to assess distant disease * Karnofsky Performance Status (KPS) 60 or above * Informed consent obtained prior to study entry Exclusion Criteria: * Patients who have metastatic disease * Pregnant women * Women of childbearing potential and male participants must practice adequate contraception. * Disease pathology other than sarcoma subtypes * Patients with a history of metastatic disease from a primary other than sarcoma * Patients who cannot undergo MRI as part of pre-treatment or treatment planning process * STS of non-extremity or chest-wall regions * Tumor size ≥ 20 cm maximal dimension

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Soft tissue sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Froedtert Hospital

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.